Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
53 Results for "
SDF-1
" in MedChemExpress (MCE) Product Catalog:
Products (53)
53 Results for "SDF-1" in MCE Product Catalog:
13
13 Publications Verification
Target:
Research Areas:
4
3
3 Cited Publications
Research Areas:
WZ811 is an orally active, highly potent competitive antagonist of CXCR4. WZ811 efficiently inhibits CXCR4/SDF-1 (or CXCL12)-mediated modulation of cAMP levels (EC50=1.2 nM) and SDF-1 induced Matrigel invasion in cells (EC50=5.2 nM) [1].
3
3 Cited Publications
Cat. No.: HY-P70469
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Stromal Cell-Derived Factor 1; SDF-1; hSDF-1; C-X-C Motif Chemokine 12; Intercrine Reduced in Hepatomas; IRH; hIRH; Pre-B Cell Growth-Stimulating Factor; PBSF; CXCL12; SDF1; SDF1A; SDF1B
2
2 Cited Publications
Target:
Research Areas:
CXCR7 antagonist-1 is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases [1].
2
2 Cited Publications
Target:
Research Areas:
CXCR7 antagonist-1 hydrochloride is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 hydrochloride is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases [1].
2
2 Cited Publications
Cat. No.: HY-P4911A
Target:
Research Areas:
2
2
2
1
1 Cited Publications
Target:
Research Areas:
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor. TL-895 is active against recombinant BTK (average IC50: 1.5 nM) and inhibits only three additional kinases BLK, BMX (IC50 = 1.6 nM) and TXK with IC50 within tenfold of BTK activity. TL-895 inhibits BTK auto-phosphorylation at the Y223 phosphorylation site (IC50: 1-10 nM). The TL-895 effectively inhibits the production of inflammatory factors such as IL-8, IL-1β, MCP-1 and TNF-α by monocytes or macrophages, and reduces the chemotactic migration of MF cells towards SDF-1. TL-895 is used be for studies of chronic lymphocytic leukemia (CLL), myelofibrosis (MF), and B-cell malignancies [1] .
1
1 Cited Publications
Cat. No.: HY-P7061A
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P700219AF
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CXCL12; Stromal cell-derived factor 1; SDF-1; 12-O-tetradecanoylphorbol 13-acetate repressed protein 1; TPAR1; C-X-C motif chemokine 12; Pre-B cell growth-stimulating factor; PBSF; Thymic lymphoma cell-stimulating factor; TLSF; SDF1
Cat. No.: HY-P3612
CAS No.: 577782-52-6
Target:
Research Areas:
Cat. No.: HY-W704574
CAS No.: 77102-28-4
Research Areas:
Mergetpa is a reversible Arg-carboxypeptidase inhibitor with high affinity. Mergetpa reduces B1R. Mergetpa blocks the overexpression of IL-1β protein and mRNA in glucose-fed rats. Mergetpa significantly increases the expression of IL-1β protein in the renal cortex. Mergetpa is used to block the conversion of kinins and B2 receptor antagonists into metabolites lacking the C-terminal arginine. Mergetpa inhibits the time-dependent enhancement of the response of isolated rabbit aorta to bradykinin. Mergetpa preserves the chemotactic activity of full-length SDF-1α on cells. Mergetpa reverses hyperglycemia, excessive weight gain, elevated levels of oxidative stress markers and overexpression of inflammatory markers in glucose-fed rats [1] .
Cat. No.: HY-P2263
CAS No.: 800379-47-9
Target:
Research Areas:
Cat. No.: HY-P10427
Target:
Research Areas:
Cat. No.: HY-P4911
CAS No.: 1268129-65-2
Target:
Research Areas:
Cat. No.: HY-P990390
Target:
Research Areas:
Cat. No.: HY-122058A
CAS No.: 2253744-59-9
Research Areas:
KRH-3955 hydrochloride is an orally bioavailable CXCR4 antagonist. KRH-3955 hydrochloride inhibits SDF-1α binding to CXCR4 with an IC50 of 0.61 nM. KRH-3955 hydrochloride is also a highly potent and selective inhibitor of X4 HIV-1, with an EC50 of 0.3 to 1.0 nM [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
